Linda: Deal trends- recent increase in value for later stag

August 2025- Pullan's Pieces #217

Linda: Midsize company landscape - partnering perspective

Kristine: Royalty rates in biopharma licensing

Eric:  Heart Failure

Trevor:  A Corner on Market Sentiment:  XBI and S&P  

July 2025- Pullan's Pieces #216 

Linda: China vs Other Countries - compete or collaborate?

Kristine: Neuroscience - new directions, partnerships, investments

Eric:  Austranada - comparing Canada and Australia

Trevor:  with ChatGPT- The AI Natives are Restless

June 2025- Pullan's Pieces #215 

 Linda: The Problems with Deal Averages 

Kristine: Targets, Progress and Deals in ALS

Eric:  World Tour of Top 10 Sellers

Trevor:  Unprecedented Precedents Ahead?

May 2025 - Pullan's Pieces #214
Linda: Fosun Snapshot
Kristine:  Biotech Innovators as First-Time Launchers
Eric:  Translational research

Trevor:  Forecasted Fundamentals Looking Good

April 2025- Pullan's Pieces #213
Linda: Shift in deal stage?
Kristine:  AI in Biotech and Pharma

Eric: More on AI
Trevor:  Head and shoulders?

March 2025- Pullan's Pieces #212
Linda: Big pharma deals in 2025?
Linda:  Big pharma unprecedented targets in CV, CNS, metabolic
Kristine:  ADC Trends
Trevor:  Soft landing optimism

February 2025 - Pullan's Pieces #211
Linda: Rare disease landscape
Linda:  RNA binding proteins
Kristine:  China Biotech
Trevor:  The money-spending business

January 2025 - Pullan's Pieces #210
Linda:  Amgen- an evolving company
Kristine:  Anti-PD1xVEGF opportunity
Trevor:  Seed to series A